Skip to content
HowShorted

Global Blood Therapeutics, Inc. short interest in 2018

In 2018, Global Blood Therapeutics, Inc.'s disclosed short interest ran from 12.25% of shares outstanding on 12 Jan 2018 to 16.15% on 31 Dec 2018, a change of +3.90 percentage points. The year's high was 18.98% on 15 Nov 2018 and its low 8.85% on 15 May 2018, averaging 12.98% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.46 days on 28 Sep 2018. Full history: Global Blood Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Global Blood Therapeutics, Inc. in 2018

2018 in figures

Start of year
12.25% (12 Jan 2018)
End of year
16.15% (31 Dec 2018)
Change
+3.90 pp
High
18.98% (15 Nov 2018)
Low
8.85% (15 May 2018)
Average
12.98%
Highest days to cover
12.46 (28 Sep 2018)
SEC filings marked
8

Every report in 2018

Global Blood Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201812.25%2.93
31 Jan 201811.92%5.46
15 Feb 201811.12%5.72
28 Feb 201810.74%6.2510-K filed, results (8-K)
15 Mar 201811.93%4.05
29 Mar 201810.34%4.27
13 Apr 201810.59%6.64
30 Apr 20189.57%9.52
15 May 20188.85%7.4110-Q filed, results (8-K)
31 May 20189.19%7.29
15 Jun 20189.08%4.41
29 Jun 201812.96%1.97
13 Jul 201812.25%5.52
31 Jul 201813.86%8.11
15 Aug 201813.45%7.5110-Q filed, results (8-K)
31 Aug 201814.41%10.97
14 Sep 201814.65%9.48
28 Sep 201815.69%12.46
15 Oct 201813.03%6.19
31 Oct 201817.70%6.73
15 Nov 201818.98%10.5110-Q filed, results (8-K)
30 Nov 201817.50%9.79
14 Dec 201815.26%2.65
31 Dec 201816.15%7.50

See also: Global Blood Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.